Leveret Mini – a hormonal contraceptive for system application.

Structure

• 1 tablet contains 0.1 mg of levonorgestrel and 0.02 mg of ethinylestradiol;
• other components: waterless lactose, K-30 povidone, magnesium stearate;
film cover contains
• : polyvinyl alcohol, talc (E 553b), titan dioxide (E 171), makrogol/PEG 3350, dye red aluminum (E 129), lecithin (E 322), ferrous oxide red (E 172), dye (E 132).

Contraindication

• a disease of a liver in a severe form, available in the anamnesis until indicators of function of a liver do not return to norm limits;
• existence or the instruction in the anamnesis on a liver tumor (benign or malignant);
• diagnosed or under suspicion hormonedependent malignant tumors (for example, genitals or mammary glands);
• vaginal bleeding of the obscure etiology;
• hypersensitivity to active ingredients (levonorgestrel, ethinylestradiol) or to any excipient of medicine;

Route of administration

is Accepted inside in the order specified on packing, approximately at the same time on one tablet a day, washing down with a small amount of liquid.

If the woman in the previous cycle did not apply contraceptive, the first pill begins to be taken in the 1st day for the beginning of periods and applied on 1 tablet a day within 21 days (it is desirable at the same time day). The beginning of reception for 2-7 days also perhaps, but during the first cycle is recommended to use in addition a non-hormonal method of contraception (such as condoms or means destroying spermatozoa) during the first 7 days of reception of tablets.

After the termination of a 21-day course of use of medicine take a 7-day break during which usually there comes menstrualnopodobny bleeding (usually for the 2nd or 3rd day). Reception of tablets from the following packing needs to be begun after a 7-day break even if bleeding did not expire.

Feature of application

in the presence of any diseases / risk factors provided below should estimate favorable effects of the CPC and possible risks of their application for the specific woman and to discuss with it the corresponding advantage and risk before she makes the decision on use of such medicines. At the first manifestation, deterioration or aggravation of any of these diseases or risk factors the woman needs to consult with the doctor. The doctor has to resolve an issue of the termination of reception of the Code of Criminal Procedure.

Pregnant

pass it is contraindicated for application during pregnancy.

Drug is not intended by

for use to children.

by

Drivers

At the women using the PDA observed no influence on ability to steer vehicles and to operate mechanisms.

Overdose

Symptoms which can be observed at overdose: nausea, vomiting, mammary gland pains, dizziness, an abdominal pain, drowsiness/weakness and vaginal bleeding at young girls.

Side effects

Infectious and parasitic diseases: a vaginitis, including vaginal candidiasis.

Benign, malignant and not specified new growths (including cysts and polyps): hepatocellular carcinoma, benign tumors of a liver (focal nodular hyperplasia, liver adenoma).

from the immune system: hypersensitivity, anaphylactic reactions with very exceptional cases of a small tortoiseshell, an angiodem, violation of blood circulation and heavy violations of breath.

from mentality: change of mood, including a depression, change of a libido.

Special storage conditions does not demand

.

Drug to store

out of children's reach.